Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials

Prospective Assessment of Pemetrexed or Pemetrexed Plus Platinum in Combination With Gefitinib or Erlotinib in Patients With Acquired Resistance to Gefitinib or Erlotinib: A Phase II Exploratory and Preliminary Study

“…15 No patients experienced grade 3 or higher diarrhea. Although a high risk of interstitial lung disease was reported in Asian patients who were treated with TKIs, 43 no patient developed interstitial lung disease in the present study. A randomized controlled phase II study compared pemetrexed and erlotinib either as single agents or in combination as second-line treatment in a clinically selected population of never smokers with NSCLC; although the combination was more toxic, it was clinically manageable.…”

Comorbidities in interstitial lung diseases

“…They have been associated with drug-induced ILD and fatal ILDs. The risk is higher in patients who receive EGFR-TKIs in association with or after chemotherapy [131]. Nintedanib, an intracellular inhibitor recently recommended for the treatment of IPF, targets multiple tyrosine kinases receptors, and is also used in the treatment of NSCLC and ovarian cancer.…”

Utility of stereotactic ablative radiotherapy/stereotactic body radiation therapy in the setting of oligometastatic non-small cell lung cancer

“…There is limited data in regards to concurrent SABR and targeted therapy, so it is difficult to say at this time if such a treatment course is appropriate for patients without risking undue toxicity from co-administration (13). EGFR inhibitors in particular have been reported to have possibility of pulmonary toxicity which may limit ability to be employed concurrently with radiation therapy (14).…”